Biotechnology
Pharmaceutical
Biopharmaceutical

MannKind

$1.99
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.15 (-7.04%) Today
+$0.01 (0.51%) After Hours

Why Robinhood?

You can buy or sell MannKind and other stocks, options, ETFs, and crypto commission-free!

About

MannKind Corporation Common Stock, also called MannKind, is a biopharmaceutical company. It focuses on the discovery, development and, commercialization of therapeutic products for diseases, such as diabetes and cancer. Read More The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Westlake Village, CA.

Employees
225
Headquarters
Westlake Village, California
Founded
1991
Market Cap
398.37M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
3.18M
High Today
$2.14
Low Today
$1.93
Open Price
$2.13
Volume
2.90M
52 Week High
$3.04
52 Week Low
$0.94

Collections

Biotechnology
Pharmaceutical
Biopharmaceutical
Health

News

Seeking AlphaMar 23

MannKind - Afrezza Scripts Still Flat Despite Advertising

When the new year arrived, MannKind (MNKD) investors had an air of excitement. The company was flush with $70 million in cash and had announced that it would initiate its largest television advertising campaign and launch a direct to consumer purchase program which would give great pricing on Afrezza to the first 1,000 patients. The advertising started with a bang, logging two consecutive weeks where ad spots topped 300 airings. Since then the campaign has become a bit more modest. The Direct to Consumer p...

249
Seeking AlphaMar 19

MannKind May Need To Sell Its Only FDA Approved Medication Afrezza To Advance Its Pipeline

To ensure access to Afrezza for adults and children in the future, it may be in MannKind's best interests to sell Afrezza to a committed partner.

99
Seeking AlphaMar 16

MannKind - Scripts, Sponsorships, Warrants

MannKind (MNKD) investors are quite a happy bunch over the past week or so. The stock has marched above $2.00 per share, and the company seems to have been able to put a bit of news on the table with an Associate Sponsorship of an Indy car participating in the Indianapolis 500. It also appears that the previously undisclosed compound in a deal with United Therapeutics (NASDAQ:UTHR) has been unearthed. Before getting into scripts, let's cover the other news. The undisclosed compound appears to be Adcirca, c...

262

Earnings

-$0.35
-$0.25
-$0.16
-$0.06
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
—
Actual
Expected May 9, Pre-Market

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.